Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Increased risk of suicidal thoughts and behaviour
The FDA today notified healthcare professionals that a range of anti-epileptic products, including { drug_name }, were associated with a significantly higher risk of suicidal thoughts and behavior (0.43% vs 0.23%) than placebo in clinical trials. This increased risk was observed as early as one week after starting the antiepileptic drug and continued through 24 weeks. These results were consistent amongst the eleven drugs studied, and the FDA believes that this risk is likely to be shared by all antiepileptic medications. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.htm
Learn More

Increased risk of suicidal thoughts and behaviour
The FDA today notified healthcare professionals that a range of anti-epileptic products, including { drug_name }, were associated with a significantly higher risk of suicidal thoughts and behavior (0.43% vs 0.23%) than placebo in clinical trials. This increased risk was observed as early as one week after starting the antiepileptic drug and continued through 24 weeks. These results were consistent amongst the eleven drugs studied, and the FDA believes that this risk is likely to be shared by all antiepileptic medications. For more information, please visit: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107834.htm
Learn More